X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs STERLING BIOTECH - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD STERLING BIOTECH ALEMBIC LTD/
STERLING BIOTECH
 
P/E (TTM) x 52.3 -0.4 - View Chart
P/BV x 2.2 0.0 15,729.1% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 ALEMBIC LTD   STERLING BIOTECH
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
STERLING BIOTECH
Dec-13
ALEMBIC LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs7211 685.7%   
Low Rs343 997.1%   
Sales per share (Unadj.) Rs4.726.8 17.5%  
Earnings per share (Unadj.) Rs6.1-15.0 -40.8%  
Cash flow per share (Unadj.) Rs6.2-5.5 -114.3%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.754.9 74.1%  
Shares outstanding (eoy) m267.03267.87 99.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.30.3 4,344.8%   
Avg P/E ratio x8.7-0.5 -1,867.0%  
P/CF ratio (eoy) x8.5-1.3 -666.4%  
Price / Book Value ratio x1.30.1 1,028.3%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,1391,862 759.5%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m207547 37.9%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m1,2557,181 17.5%  
Other income Rs m37043 869.0%   
Total revenues Rs m1,6257,223 22.5%   
Gross profit Rs m111947 11.7%  
Depreciation Rs m382,543 1.5%   
Interest Rs m24,377 0.0%   
Profit before tax Rs m442-5,931 -7.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m24-1,924 -1.2%   
Profit after tax Rs m1,630-4,007 -40.7%  
Gross profit margin %8.913.2 67.1%  
Effective tax rate %5.432.4 16.7%   
Net profit margin %129.8-55.8 -232.7%  
BALANCE SHEET DATA
Current assets Rs m1,86714,335 13.0%   
Current liabilities Rs m59149,809 1.2%   
Net working cap to sales %101.6-494.0 -20.6%  
Current ratio x3.20.3 1,097.4%  
Inventory Days Days94403 23.4%  
Debtors Days Days74171 43.1%  
Net fixed assets Rs m1,79155,432 3.2%   
Share capital Rs m534268 199.4%   
"Free" reserves Rs m10,32413,935 74.1%   
Net worth Rs m10,85814,701 73.9%   
Long term debt Rs m419,478 0.4%   
Total assets Rs m11,59173,988 15.7%  
Interest coverage x260.9-0.4 -73,496.1%   
Debt to equity ratio x00.6 0.6%  
Sales to assets ratio x0.10.1 111.6%   
Return on assets %14.10.5 2,810.3%  
Return on equity %15.0-27.3 -55.1%  
Return on capital %15.2-6.4 -236.4%  
Exports to sales %1.525.9 6.0%   
Imports to sales %21.00.2 12,348.4%   
Exports (fob) Rs m191,860 1.0%   
Imports (cif) Rs m26312 2,158.5%   
Fx inflow Rs m191,860 1.0%   
Fx outflow Rs m26425 1,059.9%   
Net fx Rs m-2441,835 -13.3%   
CASH FLOW
From Operations Rs m2361,719 13.7%  
From Investments Rs m-224-3,148 7.1%  
From Financial Activity Rs m-271,426 -1.9%  
Net Cashflow Rs m-15-3 435.3%  

Share Holding

Indian Promoters % 64.0 33.9 188.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.0 -  
FIIs % 9.7 9.9 98.0%  
ADR/GDR % 0.0 16.9 -  
Free float % 26.1 39.3 66.4%  
Shareholders   54,701 21,482 254.6%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   STRIDES SHASUN LTD  AJANTA PHARMA  SUVEN LIFE  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare ALEMBIC LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Strong; Capital Goods Stocks Lead Gains(12:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY18); Net Profit Up 64.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC LTD has posted a net profit of Rs 46 m (up 64.9% YoY). Sales on the other hand came in at Rs 332 m (up 0.9% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Oct 16, 2018 01:23 PM

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD - CADILA HEALTHCARE COMPARISON

COMPARE ALEMBIC LTD WITH

MARKET STATS